Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of SAH~2. Presence of unsecured aneurysm~3. Patient age between 18 and 80 years~4. Hunt and Hess grade \<5 (non-sedated-paralyzed pt)~5. Glasgow Coma scale \>4 (non-sedated-paralyzed pt)~6. BP above the pre-specified upper limit set by MD~7. Patient has not received pressors or inotropes~8. Patient has not received IV anti-hypertensives for more than 5 minutes (sodium nitroprusside infusion should be stopped as clevidipine is started~9. Patient has given informed consent~Exclusion Criteria:~1. Patient is \<18 or \>80 years of age~2. Patient has Traumatic SAH~3. Patient has Perimesencephalic SAH~4. Hunt and Hess grade 5 (deeply comatose/ brain dead)~5. Glasgow Coma scale 3 or 4 (deeply comatose/brain dead)~6. Patient on pressors or anti-hypertensives for more than 5 minutes~7. SBP \< 90 mm Hg~8. Heart rate \>110~9. Patient with Left BBB~10. Patient with a permanent ventricular pacemaker~11. Known allergy to dihydropyridines or clevidipine~12. Known allergy to soy products, beans, eggs or egg products22. Patients with defective lipid metabolism or pathologic hyperlipidemia or lipid nephrosis~13. Acute pancreatitis, accompanied by hyperlipidemia~14. Severe aortic stenosis~15. Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clevidipine butyrate injectable emulsion (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).